Novartis is trialling artificial intelligence (AI) in settings across drug discovery and drug development to help its scientists improve decision making.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh